Hepatic artery infusion pump chemotherapy for unresectable intrahepatic cholangiocarcinoma: Pooled individual patient-level analysis of four clinical trials
Listen to this summary
The authors aimed to assess long-term overall survival (OS) in patients with unresectable, liver-confined intrahepatic cholangiocarcinoma (iCCA) treated with hepatic artery infusion pump (HAIP) chemotherapy. By pooling individual patient data from four phase II trials involving 142 patients, they found a median OS of 26 months, with 3-year and 5-year OS rates of 28% and 15%, respectively. These results provide critical long-term survival benchmarks and support the evaluation of HAIP chemotherapy in future treatment strategies for this challenging condition.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Journal of hepatology
View all →Jun 24, 2026 · Journal of hepatology
Regression of liver cirrhosis
Jun 22, 2026 · Journal of hepatology
The Hepato-Exposome Axis: How Endocrine Disruptors Hijack Liver Receptors to Drive MASLD
Jun 20, 2026 · Journal of hepatology
MRI-based prediction of very early recurrence within 1 year after resection of HCC: An international cohort study
Jun 18, 2026 · Journal of hepatology
Interleukin-19 ameliorates drug-induced liver injury by limiting proinflammatory macrophage infiltration via SUMOylation of C/EBPβ
Jun 17, 2026 · Journal of hepatology
Impaired glycoRNA biogenesis in metabolic-dysfunction associated steatotic liver disease
Jun 15, 2026 · Journal of hepatology
A myeloid immunosuppressive phenotype defines primary refractoriness to atezolizumab Plus bevacizumab in hepatocellular caarcinoma
More in Internal Medicine
View all →Jun 25, 2026 · Blood
Combining Quizartinib with intensive chemotherapy in older patients with newly diagnosed AML: results of the UK NCRI AML18 Trial
Jun 25, 2026 · Blood
Translational Regulation of Sf1 Integrates Alternative Splicing and Hematopoietic Stem Cell Fate
Jun 25, 2026 · Blood
Galectin-1 Fuels Monocyte Hyperinflammation and Represents a Novel Therapeutic Target in Myeloproliferative Neoplasms
Jun 25, 2026 · The American journal of sports medicine
Association of Central Acetabular Osteophytes With Microinstability and Increased Combined Anteversion in Borderline Dysplasia Hips
Jun 25, 2026 · Blood
NG2-ITGA4 axis regulates Rho GTPases and leukemic aggressiveness in KMT2A-r B-ALL and is targetable with natalizumab
Jun 24, 2026 · Lancet (London, England)
Safety, pharmacokinetics, and exploratory efficacy of the oral ghrelin receptor agonist AC01 in heart failure with reduced ejection fraction (GOAL-HF1): a randomised, double-blind, placebo-controlled, phase 1b/2a study
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
